SHIN NIPPON BIOMED.LAB. financial statements, including revenue, expenses, profit, and loss

The total revenue of YB3 for the last quarter is 39.17 M EUR, and it's 1.79% higher compared to the previous quarter. The net income of Q3 23 is 5.32 M EUR.